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The expression of vascular endothelial growth factor
mRNA and protein is regulated by a number of
agents including growth factors, cytokines, and
phorbol esters. Here we report that vascular
endothelial growth factor is able to increase its own
level in cultured human dermal microvascular
endothelial cells. Accumulation of vascular endothe-
lial growth factor mRNA and polypeptide can be
detected as early as 4 h after addition of vascular
endothelial growth factor to the cell culture medium.
The autocrine action of vascular endothelial growth
factor appears to be mediated by the KDR receptor.
The increase of its own message by vascular
endothelial growth factor is blocked by the transcrip-
tion inhibitor actinomycin D. Transient transfection
experiments performed with human dermal micro-
vascular endothelial cells and using a 3.2 kb human
vascular endothelial growth factor promoter frag-
ment showed that vascular endothelial growth factor
auto-induction can be mimicked at the promoter
level. This indicates that the observed vascular
endothelial growth factor mRNA increase after vas-
cular endothelial growth factor treatment is occur-
ring at the level of transcription. Furthermore,
vascular endothelial growth factor auto-induction
is inhibited by PD 098059, showing that phosphoryl-
ation events, catalyzed by mitogen activated
protein kinases, are a prerequisite for the vascular
endothelial growth factor effect. Examination of
extracellular signal-regulated kinase and c-Jun N-ter-
minal protein kinase catalytic activities showed
that both enzymes have to be activated to mediate
the vascular endothelial growth factor signal. Our
data demonstrate for the ®rst time the existence
of an autocrine loop for vascular endothelial growth
factor in endothelial cells. Most probably this repre-
sents an ampli®cation mechanism for the action
of vascular endothelial growth factor in the micro-
vascularization process. Key words: human dermal
microvascular endothelial cells/VEGF. J Invest Dermatol
116:525±530, 2001
V
ascular endothelial growth factor (VEGF) or
vascular permeability factor, a glycosylated poly-
peptide of 40±45 kDa, is a speci®c mitogen of
endothelial cells and is the major factor responsible
for the induction of angiogenesis (Keck et al, 1989;
Leung et al, 1989; Ferrara, 1993). Several isoforms of VEGF
resulting from the alternative splicing of its gene have been
described (Tischer et al, 1991); the larger forms, VEGF189 and
VEGF206, remain cell-associated whereas the two smaller forms,
VEGF121 and VEGF165, are secreted (Ferrara et al, 1992). The
level of VEGF is upregulated in a number of pathologic
situations such as diabetic retinopathy, psoriasis (Detmar et al,
1994), rheumatoid arthritis (Fava et al, 1994), and cancers
(Folkman, 1995). In psoriasis, for example, epidermal keratino-
cytes over-express VEGF, which in turn induces neo-vascular-
ization through the proliferation and increased migration of
dermal microvascular endothelial cells (Detmar, 1996). VEGF
has been shown to exert its effects in endothelial cells by
interacting with two high af®nity membrane receptors display-
ing tyrosine kinase activity, Flt-1 and KDR (Terman et al,
1992; Quinn et al, 1993). A third class of receptor for VEGF,
neuropiline-1 and -2, has been recently described (Soker et al,
1998). Upregulation of VEGF mRNA and protein expression
has been demonstrated in a number of in vitro and in vivo
models. VEGF level is controlled by certain growth factors and
cytokines such as interleukin-6 (Cohen et al, 1996), epidermal
growth factor, platelet derived growth factor, transforming
growth factor b1 (TGF-b1), tumor necrosis factor a (TNFa),
and keratinocyte growth factor (Frank et al, 1995). Hypoxia
occurring in certain pathologic situations also leads to an
increase in VEGF expression (Ikeda et al, 1995; Stein et al,
1995; Shima et al, 1996). A 3.4 kb VEGF promoter fragment
has been cloned (Tischer et al, 1991) and shown to contain
functional sites for the binding of transcription factors important
for controlling VEGF expression. These factors include hypoxia
induced factor (Forsythe et al, 1996), AP1 (Vega-Diaz et al,
2000), SP1 (Finkenzeller et al, 1997), and AP2 (Gille et al,
1997). In this report, we characterize a VEGF autocrine loop
occurring in human dermal microvascular cells (HDMEC), one
of the speci®c targets of VEGF action. This autocrine loop
certainly provides an ampli®cation mechanism for VEGF-driven
angiogenesis.
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MATERIALS AND METHODS
Materials Recombinant VEGF was from Pepro Tech EC (Rocky Hill,
NJ). Antibodies and protein substrates for the determination of MAP
kinase activity were from Santa Cruz Biotechnology (Santa Cruz, CA)
and Sigma. PD 098059 was purchased from TEBU (Paris). Actinomycin
D was purchased from Sigma. Antibodies against KDR or Flt-1 VEGF
receptors and VEGF were from R&D Systems (Abingdon, U.K.).
Cell culture conditions HDMEC were either purchased from
Clonetics or isolated from human skin obtained from plastic surgery.
They were grown in endothelial basal medium (EBM-2; Clonetics)
supplemented with 5% (vol/vol) fetal bovine serum and bovine pituitary
extract, epidermal growth factor, hydrocortisone, gentamicin,
amphotericin-B, VEGF, and ®broblast growth factor (FGF) at
concentrations recommended by the manufacturer. For all experiments,
third passage subcon¯uent HDMEC cultures grown in 60 mm dishes
were ®rst incubated for 24 h in EBM-2 devoid of FGF and VEGF but
containing 2% (vol/vol) fetal bovine serum. Then they were treated for
different periods of time with or without recombinant VEGF.
In some experiments, 1 h before the addition of recombinant VEGF,
a polyclonal antibody directed against VEGF, KDR VEGF receptor, or
Flt-1 VEGF receptor was added to the culture medium, at concentrations
recommended by the manufacturer.
RNA isolation Total RNA was isolated from cultured HDMEC using
the Trizol method (Gibco), according to the manufacturer's procedure,
and stored at ±80°C until use.
Reverse transcriptase polymerase chain reaction (RT-PCR) and
semiquantitative PCR The following primers for PCR were
synthesized by Gibco (France): glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) sense (5¢-AATCCCATCACCATCTTCCA-3¢) and
antisense (5¢-GTCATCATATTTGGCAGGTT-3¢) oligonucleotides;
VEGF sense (5¢-CCATGAACTTTCTGCTGTCTT-3¢) and anti-sense
(5¢-ATCGCATCAGGGGCACACAG-3¢) oligonucleotides. The ampli®-
cation products were predicted to be 558 bp for GAPDH and 249 bp
for VEGF. The VEGF primers were chosen in exon 1 and exon 3 of the
VEGF gene resulting in a PCR product of 294 bp irrespective of the
splice form produced (Vega-Diaz et al, 2000).
RT-PCR was carried out using 5 mg of total RNA extracted from
cultured endothelial cells. After denaturation in diethylpyrocarbonate-
treated water for 10 min at 70°C, RNA was reverse-transcribed into
®rst-strand cDNA using SuperScriptII Rnase H reverse transcriptase (10
units per reaction, Gibco BRL) and 0.5 mg of oligo (dT) as primer, at
42°C for 50 min in a total volume of 20 ml in a buffer containing
20 mM Tris-HCl, pH 8.4, 50 mM KCl, 1.5 mM MgCl2, 1 mM dNTP,
10 mM dithiothreitol, and 20 units Rnasin. Reverse transcriptase was
inactivated at 70°C for 15 min and the RNA template was digested by
Rnase H at 37°C for 20 min. Each experiment included samples devoid
of reverse transcriptase (negative controls) to exclude ampli®cation from
contaminating genomic DNA. Semiquantitative RT-PCR ampli®cation
was performed with a PTC 225 thermal cycler (MJ Research), following
a 1 min period of denaturation at 94°C, under the following conditions:
denaturation at 94°C for 30 s, annealing at 55°C for 30 s, and extension
at 72°C for 30 s, for the total number of cycles indicated below. The
assay mixture contained 20 mM Tris-HCl, pH 8.4, 50 mM KCl,
1.5 mM MgCl2, 0.1 mM of oligonucleotide primers, dNTPs (100 mM of
dATP, dGTP, dTTP, 10 mM dCTP), 0.5 mCi of [32P]-dCTP, 0.5 units
of Taq DNA polymerase, and 5 ml of a 100-fold diluted cDNA mixture.
The ®nal product was extended for 3 min at 72°C. In each experiment,
reverse transcriptase positive controls (templates containing cDNA
encoding for VEGF) and negative control (without DNA) were
included. The PCR products were subjected to electrophoresis on 6%
(wt/vol) acrylamide gels. Radioactivity in each band was quanti®ed by
the storage phosphorimaging technique. The screens were scanned using
a Fuji BAS 2000. The signal was quanti®ed in photo stimulating
luminescence units using the Tina image analysis software. Results were
expressed for each sample as band intensity relative to that of GAPDH.
An optimum number of PCR cycles was determined in the region of
exponential ampli®cation. It was determined to be 28 cycles for VEGF
and 22 cycles for GAPDH. Logarithmic dilutions of the cDNA mixture
were used to verify the linear correlation between the intensity of the
radioactive signal and the initial amount of cDNA.
VEGF radioimmunoassay HDMEC cells were labeled overnight
with 250 mCi [35S]-cysteine per ml of culture medium before being
incubated with VEGF at 20 ng per ml. At different time points, the
medium was collected. The attached cells were lyzed with 50 mM
HEPES, pH 7.6, 250 mM NaCl, 3 mM ethylenediamine tetraacetic acid
(EDTA), 3 mM ethyleneglycol-bis(b-aminoethyl ether)±N,N,N¢,N¢-
tetraacetic acid (EGTA), 0.5% (vol/vol) Nonidet P-40, and 1% (vol/vol)
Triton X-100 containing 1 mM phenylmethylsulfonyl ¯uoride (PMSF),
10 mg per ml leupeptin, and 10 mg per ml aprotinin as protease
inhibitors. The lysates were subjected to low speed centrifugation. The
cell supernatant and the culture medium were added to an enzyme-
linked immunosorbent assay (ELISA) plate (R&D Systems) and VEGF
was bound by the immobilized antibody. VEGF ELISA was performed
as described by the manufacturer except that addition of the conjugate
was omitted and the plates were directly subjected to scintillation
counting (Wallac Microbeta Trilux EG & G).
VEGF immunoprecipitation HDMEC were labeled overnight with
250 mCi [35S]-cysteine per ml of culture medium before being incubated
with VEGF at 20 ng per ml. At different time points, the medium was
collected. The attached cells were lyzed with 50 mM HEPES, pH 7.6,
250 mM NaCl, 3 mM EDTA, 3 mM EGTA, 0.5% (vol/vol) Nonidet
P-40, and 1% (vol/vol) Triton X-100 containing 1 mM PMSF, 10 mg
per ml leupeptin, and 10 mg per ml aprotinin as protease inhibitors. The
lysates were subjected to low speed centrifugation and the supernatants
were incubated with a polyclonal anti-VEGF antibody or with an
unrelated polyclonal anti-PPAR-a antibody used as a control. The
mixture was then incubated with Protein G-Sepharose. After
centrifugation, the Sepharose beads were incubated with sodium dodecyl
sulfate (SDS) sample buffer. The immunoprecipitated proteins were then
separated by SDS polyacrylamide gel electrophoresis using non-reducing
conditions. The gels were exposed to a phosphorimager screen.
Transfection of endothelial cells and VEGF transactivation
assay HDMEC were transiently transfected in 60 mm culture dishes
using Superfect (Quiagen) according to the manufacturer's procedure.
We used 5 mg of a construct that contained a 3.2 kb fragment of the
human VEGF promoter cloned into the pGl2-basic vector luciferase
reporter plasmid (Ikeda et al, 1995). The plasmid was kindly provided by
Drs A. Damert and W. Risau (Max-Plank-Institut fuÈr physiologische
und klinische Forschung, Bad Nauheim, Germany) with the permission
of Dr. J. Abraham (Scios Nova, Sunnyvale, CA). Transfected cells were
transferred into 10 wells of a 96-well plate for 48 h and treated either
with or without 20 ng per ml VEGF or 100 nM 12-O-
tetradecanoylphorbol-13-acetate (TPA) (Sigma) for 4 h. Luciferase
activity was determined using the LucLite kit (Packard) and the
luminescence counter Wallac Microbeta Trilux.
In vitro kinase assay HMDEC were lyzed in cell extraction buffer
containing 50 mM HEPES, pH 7.6, 250 mM NaCl, 3 mM EDTA,
3 mM EGTA, 0.5% Nonidet P-40, 100 mM Na3VO4, 50 mM b-
glycerophosphate, 2 mM sodiumpyrophosphate, 1% Triton X-100 and
the protease inhibitors PMSF (1 mM), leupeptin (10 mg per ml), and
aprotinin (10 mg per ml). The cell lysate was clari®ed by centrifugation
(15,000 3 g, 10 min, 4°C) and equal amounts of lysate were
immunoprecipitated with antijun kinase JNK or anti-ERK antibodies
and 30 ml of protein A-Sepharose for 3 h at 4°C. Immunoprecipitates
were washed three times with cold lysis buffer followed by two washes
with kinase assay buffer containing 50 mM HEPES, pH 7.6, 25 mM b-
glycerophosphate, 0.1 mM Na3VO4, and 25 mM MgCl2. Then 5 mg of
myelin basic protein (MBP) (for ERK) or 10 mg of GST-cJun (1±79)
(for JNK) in kinase buffer containing 50 mM of cold ATP and 5 mCi of
[g-32P]-ATP (> 4000 mCi per mmol; ICN) were added. The mixture
was incubated at 30°C for 20 min and the reaction was stopped by the
addition of SDS sample buffer. The samples were subjected to SDS-
polyacrylamide gel electrophoresis on a 12% (wt/vol) polyacrylamide gel.
The gels were dried and the radioactivity contained in MBP or GST-
cJun was quanti®ed by the storage phosphorimaging technique. The
screens were scanned and quanti®ed as described before.
Statistical analysis The results are presented as means (6 SEM) of the
duplicates of three independent experiments. They were analyzed using
the two-sided Student's t test (NS, not signi®cant; *p < 0.1; **p < 0.05;
***p < 0.01.
RESULTS AND DISCUSSION
The expression of VEGF mRNA and protein is regulated in a
paracrine fashion by a number of factors that include cytokines and
several growth factors (Frank et al, 1995). Cells of different origin
are able to synthesize and secrete VEGF, which is over-expressed
by malignant tumor cells (Levy et al, 1989; Conn et al, 1990;
Phillips et al, 1990; Garrido et al, 1993). VEGF is produced at the
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mRNA level by cultured cells from rat brain capillary endothelium
(Ladoux and Frelin, 1993) or by cultures of bovine glomerula
endothelial cells (Simorre-Pinatel et al, 1994; Uchida et al, 1994). A
different situation occurs in human cells, where VEGF does not
seem to be synthesized in resting cultured umbilical vein
endothelial cells or HDMEC but can be produced as a consequence
of TPA treatment or hypoxia (Namiki et al, 1995; Detmar et al,
1997). The fact that human endothelial cells can, under certain
circumstances, synthesize VEGF prompted us to verify whether or
not VEGF could regulate its own synthesis in these cells. As model
we used HDMEC in culture starved for growth factors over 24 h
and treated for different periods of time with VEGF. Total RNA
was prepared and the level of VEGF mRNA was quantitated by
using RT-PCR. As shown in Fig 1(a), small amounts of VEGF
mRNA were expressed at basal level. When VEGF at 10 ng per ml
was added to the culture medium for 4 h, however, a substantial
increase in VEGF mRNA could be observed. This upregulation by
a factor of 2.5±3 was transient as the amount returned to normal
after 16 h of incubation. The increase in VEGF message was
paralleled by an augmentation of the level of matrix metallopro-
teinase 1 and 3 mRNAs (results not shown), two markers of
endothelial cell activation, and comparable to that obtained after
treatment of HDMEC with TNFa (Fig 1b). A similar induction
level was also observed after treatement of HDMEC with TPA
(result not shown). Figure 2 shows that the maximal increase in
VEGF mRNA level was obtained at 10±20 ng per ml depending
on the batch of recombinant VEGF used. No effect was observed at
high concentration of VEGF (50 ng per ml), however, certainly
indicating downregulation of the VEGF signal in the presence of an
excess of VEGF. This may represent a protective mechanism of
HDMEC against an excess of VEGF. Figure 3 clearly shows the
speci®city of the response as the action of VEGF was blocked by
preincubation with a speci®c antibody recognizing the mature
VEGF121 and VEGF165 isoforms. To determine whether the
increase of VEGF transcript induced by VEGF was accompanied by
a corresponding rise in the production of the polypeptide, a
radioimmunoassay experiment was performed using a speci®c
antibody recognizing the mature VEGF121 and VEGF165 isoforms.
After labeling of the cells with [35S]-cysteine, the amount of VEGF
was determined both in the cell culture supernatant and in the total
cell lysate. VEGF was not detected, even after treatment with
VEGF, in the cell culture medium (not shown). As shown in
Figure 1. Time course of VEGF mRNA induction by VEGF in
cultured HDMEC. Total RNA was isolated at the indicated time
points from HDMEC following incubation in EBM-2 in the absence or
presence of 10 ng per ml VEGF (a) or 50 units per ml of TNFa (b).
The expression level of VEGF mRNA was determined relative to that of
GAPDH mRNA by semiquantitative RT-PCR analysis as described in
Materials and Methods. Results were normalized to the values obtained
with untreated cells.
Figure 2. Induction of VEGF mRNA level in cultured HDMEC
treated with different concentrations of VEGF. Total RNA was
isolated at the indicated time points from HDMEC following incubation
in EBM-2 in the absence or presence of the indicated concentrations of
VEGF. The expression level of VEGF mRNA was determined relative
to that of GAPDH mRNA by semiquantitative RT-PCR analysis as
described in Materials and Methods. Results were normalized to the values
obtained with untreated cells.
Figure 3. Effect of anti-VEGF antibody on VEGF mRNA
expression in cultured HDMEC treated with VEGF. HDMEC
were preincubated for 1 h with a polyclonal antibody raised against
VEGF (2 mg per ml) before the addition of VEGF (20 ng per ml). After
4 h, total RNA was isolated and the expression level of VEGF mRNA
was determined relative to that of GAPDH mRNA by semiquantitative
RT-PCR analysis as described in Materials and Methods. Results were
normalized to the values obtained with untreated cells.
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Fig 4(a), cell-associated VEGF polypeptides were detected in non-
treated cells and were increased up to 24 h after VEGF treatment.
In addition, cell-associated VEGF was immunoprecipitated from
total cell lysate of HDMEC treated for 4 h with VEGF (Fig 4b).
The fact that we were not able to detect signi®cant amounts of
VEGF in the cell culture supernatant is consistent with previous
®ndings (Houck et al, 1992) showing that the VEGF165 isoform can
be sequestered by the extracellular matrix of endothelial cells. These
results point to the existence of an autocrine loop for VEGF in
HDMEC. An analogous autoregulation process has already been
described for TGF-b1, which causes in various normal or
transformed ®broblasts a rapid increase in the synthesis of its own
message and in TGF-b1 secretion (Van-Obberghen-Schilling et al,
1988; Kim et al, 1989a, b, 1990). It is thought that the TGF-b1
autocrine loop could amplify the physiologic process of wound
healing. The stimulation by VEGF of its own RNA synthesis and
polypeptide production certainly provides an ampli®cation mech-
anism for the vascularization process. HDMEC express the two
VEGF receptors KDR and Flt-1, and an interesting question was to
know which of these two receptors was involved in the transmis-
sion of the VEGF signal. HDMEC were preincubated with anti-
KDR or anti-Flt-1 antibodies before addition of VEGF. As shown
in Fig 5, preincubation with anti-KDR antibody, but not with
anti-Flt-1 antibody, completely blocked the increase of VEGF
message. This shows that KDR might be involved in the VEGF
autocrine loop. This is consistent with the fact that KDR is
involved in the control of mitogenesis of endothelial cells
(Waltenberger et al, 1994; Keyt et al, 1996) and other cell types
(Dias et al, 2000).
To prove that the induction of VEGF mRNA by VEGF in
culture involves a transcriptional event, actinomycin D, an
inhibitor of transcription, was used. As shown in Fig 6,
actinomycin D reduces the basal level of VEGF mRNA and
completely abolishes the VEGF-induced mRNA synthesis.
Figure 4. Induction of VEGF polypeptide production by cultured
HDMEC treated with VEGF. (a) HDMEC were labeled with [35S]-
cysteine in EBM-2 for 24 h and then treated until the indicated time
points with or without VEGF at 10 ng per ml. The cell lysates were
collected and VEGF was quantitated using a radioimmunoassay with a
speci®c anti-VEGF antibody. (b) HDMEC were labeled with [35S]-
cysteine in EBM-2 for 24 h and then treated for 4 h without (lanes 1
and 2) or with (lanes 3 and 4) VEGF at 10 ng per ml. The cell lysate
was then immunoprecipitated with a control (lanes 1 and 3) or an anti-
VEGF antibody (lanes 2 and 4). Immunoprecipitated VEGF was revealed
by polyacrylamide gel electrophoresis and autoradiography.
Figure 5. Effect of anti-KDR or anti-Flt-1 antibody on VEGF
mRNA expression in cultured HDMEC treated with VEGF.
HDMEC were preincubated for 1 h with an antibody raised against
KDR (1 mg per ml) or Flt-1 (100 mg per ml) before the addition of
VEGF (20 ng per ml). After 4 h, total RNA was isolated and the
expression level of VEGF mRNA was determined relative to that of
GAPDH mRNA by semiquantitative RT-PCR analysis as described in
Materials and Methods. Results were normalized to the values obtained
with untreated cells.
Figure 6. Effect of actinomycin D on VEGF mRNA expression
in cultured HDMEC treated with VEGF. Semiquantitative RT-PCR
analysis was performed on total RNA from cells grown in EBM-2 and
treated for 4 h either with or without VEGF 20 ng per ml in the
presence of actinomycin D 10 mg per ml. The expression level of VEGF
mRNA was determined relative to that of GAPDH mRNA as described
in Materials and Methods. Results were normalized to the values obtained
with untreated cells.
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Cycloheximide, an inhibitor of protein synthesis, could not be used
to check if the increase of VEGF mRNA level required de novo
protein synthesis, as treatment of HDMEC with this compound
alone led to a large increase in VEGF mRNA expression. This
effect of cycloheximide on VEGF level has been well documented
in other cellular systems (Ladoux and Frelin, 1993). HDMEC in
culture were then transfected with a 3.2 kb human VEGF promoter
fragment linked to a luciferase reporter gene. As a control, cells
were also treated with TPA, a well-known activator of VEGF
promoter transactivation (Vega-Diaz et al, 2000). As shown in
Fig 7, treatment of transfected HDMEC with VEGF led to an
increase in reporter gene activity that was even greater than that
obtained with TPA. This further con®rms that VEGF auto-
induction is occurring at the transcriptional level.
Previously it has been shown that distinct phosphorylation
pathways control the transcription of the VEGF gene. For example,
the protein kinase C zeta isoform has been implicated in the
transcription of the VEGF gene induced by the SP1 transcription
factor (Pal et al, 1998). Phosphatidylinositol 3-kinase is activated in
endothelial cells when VEGF expression is induced by platelet-
derived growth factor (Wang et al, 1999). In ®broblasts the p42/
p44 mitogen activated protein (MAP) kinases play an important
role in VEGF expression (Milanini et al, 1998). VEGF binding to
the VEGF receptors activates the extracellular signal-regulated
kinase (ERK) and the c-Jun N-terminal protein kinase (JNK) in
human umbilical vein endothelial cells as well as the MAP kinase
pathway in rat cardiac myocytes (Seko et al, 1998). To gain some
insights into the molecular events occurring between the inter-
action of VEGF with KDR and the increase of VEGF at the
transcriptional level, HDMEC treated with VEGF were incubated
with the MAP kinase inhibitor PD 098059. As shown in Fig 8, PD
098059 completely abolished the induction of VEGF mRNA by
VEGF. This result led us to investigate the time course of activation
of ERK and JNK in HDMEC following VEGF stimulation. As
shown in Fig 9, activation of JNK occurred as early as 5 min after
VEGF addition whereas ERK activation increased after 5 min and
was maximum after 10 min. Our results are consistent with recent
®ndings (Pedram et al, 1998) showing that VEGF treatment of
human umbilical vein endothelial cells increases both JNK and
ERK activation. In this study ERK preceded JNK activation,
however.
In conclusion, we have demonstrated the existence of an
autocrine loop for VEGF in microvascular endothelial cells. This
certainly provides an ampli®cation mechanism for the physiologic
and pathologic microvascularization processes. The fact that the
expression by microvascular endothelial cells of the VEGF receptor
Figure 7. Effect of VEGF on the transactivation of the human
VEGF promoter in HDMEC. HDMEC were transiently transfected
with a plasmid containing a 3.2 kb human VEGF promoter fragment
cloned upstream of a luciferase reporter gene. Transfected cells grown in
EBM-2 were treated with or without VEGF 20 ng per ml or 100 nM
TPA for 4 h. Luciferase activity was determined as described in Materials
and Methods. Results were normalized to the values obtained with
untreated cells.
Figure 8. Effect of the MAP kinase inhibitor PD 098059 on
VEGF mRNA expression in cultured HDMEC treated with
VEGF. Semiquantitative RT-PCR analysis was performed on total
RNA from cells grown in EBM-2 and treated for 4 h either with or
without VEGF 20 ng per ml in the presence of PD 098059 20 mM. The
expression level of VEGF mRNA was determined relative to that of
GAPDH mRNA as described in Materials and Methods. Results were
normalized to the values obtained with untreated cells.
Figure 9. Effect of VEGF treatment of cultured HDMEC on JNK
and ERK activation. HDMEC were incubated in EBM-2 for 24 h and
then treated with or without VEGF at 10 ng per ml. Immuno-
precipitated ERK and JNK were incubated in the presence of [32P]-ATP
with their respective substrate MBP or GST-c-jun. 32P incorporation
into the substrates was revealed by polyacrylamide gel electrophoresis and
autoradiography.
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KDR is increased after VEGF treatment implies that KDR may also
contribute to the ampli®cation of the VEGF signal (Shen et al,
1998). While this work was in progress, another study reported that
autocrine stimulation of endothelial cells by VEGF can lead to
reorganization of the vascular network (Helmlinger et al, 2000).
Future studies will be dedicated to the detailed pathways involved
in VEGF auto-induction.
Thanks are due to Prof. U. Reichert, Dr. M. DeÂmarchez, and Prof. D. Dhouailly
for helpful discussions.
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